Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial

PURPOSE: In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Ryan, Charles J., Molina, Arturo, Li, Jinhui, Kheoh, Thian, Small, Eric J., Haqq, Christopher M., Grant, Russell P., de Bono, Johann S., Scher, Howard I.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2013
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569674/
https://ncbi.nlm.nih.gov/pubmed/23816964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.4595
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg